New diabetes pill rybelsus tested in everyday use
NCT ID NCT04537637
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study followed 99 adults with type 2 diabetes in Denmark who were already prescribed Rybelsus (oral semaglutide) by their doctor. Researchers tracked changes in blood sugar (HbA1c) and body weight over about 8-10 months. Participants filled out questionnaires during regular clinic visits. The goal was to see how well the medication works in real-world settings, not in a controlled lab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Master Centre for Denmark
Copenhagen S, 2300, Denmark
-
Novo Nordisk investigational site
Søborg, 2860, Denmark
Conditions
Explore the condition pages connected to this study.